Leap-011: Exploring First-Line Pembrolizumab + Lenvatinib For Advanced Urothelial Carcinoma

LEAP-011: exploring first-line pembrolizumab + lenvatinib for advanced urothelial carcinoma

LEAP-011: first-line pembrolizumab plus lenvatinib for UC

Results for First-Line Pembrolizumab in Advanced Urothelial Carcinoma

Targeted Oncology

KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCC

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progressi...

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

CLEAR: lenvatinib and pembrolizumab in advanced renal cell carcinoma

Lenvatinib plus pembro for aRCC - update on the CLEAR study

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

European Society for Medical Oncology (ESMO)

LBA41 - LEAP-005: Phase II study of lenvatinib plus pembrolizumab

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor...

Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer

Targeted Oncology

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year fol...

Lenvatinib and Pembrolizumab Compared to Sunitinib for Advanced Renal Cell Carcinoma

Lenvatinib and Everolimus for Advanced RCC

Targeted Oncology

Health-Related Quality of Life With Lenvatinib Plus Pembrolizumab for Patients With Advanced RCC

Lenvatinib Pembrolizumab in RCC, the CLEAR trial with Karine Tawagi

Vinay Prasad MD MPH

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma

KEYNOTE-775 subgroup analysis in advanced endometrial cancer

Maintenance therapy for patients with advanced urothelial carcinoma